Glaucoma Market Analysis 2026

Competitive Landscape of the Glaucoma Market

In the Glaucoma market's competitive landscape, numerous key competitors are driving innovation and growth. In order to maximize their market share, businesses are engaging in strategic initiatives such as partnerships, acquisitions, mergers, and strategic agreements with the purpose of expanding their product portfolios. In order to maintain their position in the market, businesses in the sector are putting additional emphasis on expanding their geographic reach and releasing many products.

In April 2023, At the ARVO 2023 Annual Meeting, Janssen Pharmaceutical Companies of Johnson & Johnson announced presentations that provided updates on their investigational gene therapy portfolio. These presentations included botaretigene sparoparvovec (bota-vec) for X-linked retinitis pigmentosa (XLRP) and JNJ-1887 for age-related macular degeneration (AMD). Janssen's objective is to emphasize its innovative gene therapies for retinal diseases, which have garnered substantial data on safety and efficacy from ongoing clinical trials. (Source: https://www.jnj.com/media-center/press-releases/janssen-to-highlight-innovation-in-retinal-pipeline-at-the-association-for-research-in-vision-and-ophthalmology-arvo-2023-annual-meeting) In March 2022, Oculis S.A. and Accure Therapeutics announced a licensing agreement. This agreement grants Oculis exclusive global rights to develop and commercialize ACT-01, which has been renamed OCS-05, a neuroprotective drug candidate for glaucoma. OCS-05 is currently undergoing a Phase 2a clinical trial for acute optic neuritis and has demonstrated positive results in animal models. This agreement validates Accure's strategy as a translational R&D engine in neuroscience and supports Oculis' mission to advance innovative ophthalmology treatments. (Source: https://accure.health/oculis-strengthens-leading-ophthalmology-pipeline-by-in-licensing-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/) In August 2022, Alcon Laboratories announced its intention to acquire Aerie Pharmaceuticals, Inc. for an estimated $770 million. This acquisition will expand the company's ophthalmic pharmaceutical portfolio. This strategic acquisition encompasses a promising pipeline of clinical and preclinical product candidates, as well as Aerie's commercial products, Rocklatan® and Rhopressa®. The agreement is consistent with Alcon's dedication to the development of innovative eye care treatments and is anticipated to be accretive to Alcon's core diluted EPS by 2024. Alcon's recent expansions into the ophthalmic pharmaceutical market, which include the acquisitions of Simbrinza, Eysuvis, and Inveltys, are further complemented by this acquisition. (Source: https://investor.alcon.com/news-and-events/press-releases/news-details/2022/Alcon-to-Acquire-Aerie-Pharmaceuticals-Inc.-Enhancing-its-Ophthalmic-Pharmaceutical-Portfolio/default.aspx)

SY

Supriya Yadav Verified Analyst

Research Analyst · Cognitive Market Research

Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.

Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive  research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.

In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.

Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.

Read more

LinkedIn Profile Book Appointment